Carolina de la Flor

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri et al. · The Lancet Infectious Diseases · 2021 · 170 citations · Full text

Cryopreservation modulates the detection of regulatory T cell markers

Sebastian E. Sattui, Carolina de la Flor, César Sánchez et al. · Cytometry Part B Clinical Cytometry · 2011 · 66 citations · Full text

Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study

Christina Yek, Carolina de la Flor, John K. Marshall et al. · BMC Medicine · 2017 · 57 citations · Full text

Opt-out HIV and Hepatitis C Testing at the Dallas County Jail: Uptake, Prevalence, and Demographic Characteristics of Testers

Carolina de la Flor, Esmaeil Porsa, Ank E. Nijhawan · Public Health Reports · 2017 · 41 citations · Full text

Hepatitis C Testing, Substance Abuse, Human Immunodeficiency Virus +15

What’s in a name? The heterogeneous clinical spectrum and prognostic factors in a cohort of adults with hemophagocytic lymphohistiocytosis

Bonnie C Prokesch, Srikanth Nagalla, Fatemeh Ezzati et al. · Transfusion and Apheresis Science · 2018 · 11 citations

Prognostic Factors, Lymphoid Neoplasia, Heterogeneous Clinical Spectrum +8